Logo featuring "BIOVECTRA" in purple text with a blue and yellow abstract design, and the phrase "A part of Agilent" below.
Facebook Linkedin

VIDEO

Sneak Peak of Biomanufacturing Facility

In the summer of 2023 Bryan Lowery, VP & GM mRNA Vaccine and pDNA Operations, took us around to preview our new, cutting-edge biomanufacturing facility. The facility opened it’s doors in late 2023 and is fully operational. This cGMP facility boasts 36,000 square feet of state-of-the-art manufacturing space, vaccine and therapeutic production capacity for 160 million doses each year, and fill/finish capacity for 70 million doses per year for commercial distribution.

Want to learn more?

Check out the video or request more information.

Currently Accepting New Projects


BIOVECTRA is committed to streamlining development and accelerating timelines by simplifying the supply chain for your nucleic acid drug products. ​

Our breadth of knowledge allows us to move quickly from idea to implementation. We can generate, source, or synthesize all components of LNPs, including pegylated lipids, ionizable lipids, and phospholipids.

  • cGMP manufacturing​
  • 36,000 sq ft state-of-the-art facility​
  • pDNA scales: 30 L to 1,000 L​
  • mRNA scales: 300 mL to 30 L​
  • LNP scales: ​
        100 mg to 20 grams​

© BIOVECTRA 2024. All rights reserved

SEO plus – Test

  • 20+ years at GSK, leading R&D activities on multiple vaccine programs
  • Recently held positions in industry include: Senior Director (Function Head), Protein Biochemistry; Director, Antigen Design & Prototype Production; and, Associate Director, Antigen Design and Protein Characterization.
  • Key areas of expertise are:
    • Process development of protein Biologics/Recombinant Antigens
    • Recombinant protein expression (mammalian, insect, yeast, bacterial)
    • Production/design of Viral Vectors, mRNA vaccines, Bacterial outer membrane vesicles
    • Protein Engineering and Structural Biology
    • Defining quality attributes, biophysical characterization of proteins, and analytical strategy
  • Post graduate degrees in Functional Genomics (Université Laval) and Bioinformatics (MIT); M. Sc. Microbiology and Immunology (Laval).
  • 25+ Patent & 5 Scientific Publications